Description
Altium Capital Management focuses on long-term investments in healthcare companies, providing growth capital to private and public companies developing novel technologies for human health. The firm's investment universe is concentrated in therapeutics, including private ventures and small-cap and micro-cap public companies with transformative catalysts on the horizon, many of which are raising institutional capital for the first time. Altium supports early-stage ventures in pre-clinical development phases with a view toward long-term partnerships and multiple rounds of financing, and helps portfolio companies attract additional capital through its network of like-minded investors. The firm is led by Managing Partner and Chief Investment Officer Jacob Gottlieb, who founded Visium Asset Management in 2005 (grown to ~$8 billion AUM) before founding Altium in 2017, and its team combines scientific professionals with experienced fund managers. Selected portfolio companies include Antios Therapeutics, Cerevel Therapeutics, Chemomab Therapeutics, eGenesis, Gemini Therapeutics, Hummingbird Bioscience, Hyperfine, Immunovant, Ocuphire Pharma, Palisade Bio, Quoin, Sagimet Biosciences, Seelos Therapeutics, Sonnet BioTherapeutics, Timber Pharmaceuticals, Vincerx Pharma, and Yumanity Therapeutics.